01—Abstract
Summary
Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) reported third quarter 2025 results for the period ended September 30, 2025, with total revenue of $265.2 milliona, up 39% year over year from $191.5 million.
Growth was broad-based: Oncology revenue rose 31% to $184.4 millionb on a 40% increase in test volume, Screening (Shield) contributed $24.1 million from roughly 24,000 tests versus $1.0 million a year earlier, and Biopharma & Data grew 18% to $54.7 million, partly driven by service-agreement milestone achievements. Non-GAAP gross margin expanded to 66% from 63%, and management noted the company crossed $1 billion in annualized revenue. Profitability improved meaningfully, though the company remains loss-making.
GAAP net loss narrowed to $92.7 millionc from $107.8 million, and non-GAAP net loss improved to $48.3 million from $55.0 million. Adjusted EBITDA loss narrowed to $45.5 million from $56.2 million, and free cash flow burn was $(45.8) million versus $(55.3) million. Cash, cash equivalents and restricted cash totaled $689.5 million at quarter end.
Non-GAAP operating expenses rose to $228.9 milliond from $187.3 million as the company invests in commercial expansion and the Shield launch. The key forward-looking development is a raised 2025 revenue guidance of $965 to $970 million, up from $915 to $925 million and implying about 31% growth. Screening guidance was lifted to $71 to $73 million on Shield volume of 80,000 to 82,000 tests, and the non-GAAP gross margin outlook was raised to 64% to 65%.
Management raised non-GAAP operating expense guidance to $865 to $875 million to support the Shield launch, while free cash flow burn guidance of $225 to $235 million was maintained and is an improvement over 2024. The filing is a press-release furnishing under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Total Q3 2025 revenue of $265.2M, up 39% YoY, with Oncology up 31%, Screening at $24.1M (vs. $1.0M), and Biopharma & Data up 18%
- 2025 revenue guidance raised to $965–$970M from $915–$925M, implying roughly 31% annual growth
- Screening guidance raised to $71–$73M on 80,000–82,000 projected Shield tests, up from $55–$60M
- Non-GAAP gross margin of 66% in Q3 vs. 63% a year earlier; full-year non-GAAP gross margin guidance raised to 64–65%
- GAAP net loss narrowed to $92.7M from $107.8M; Adjusted EBITDA loss narrowed to $45.5M from $56.2M
- Non-GAAP operating expense guidance raised to $865–$875M to fund Shield commercial build-out, a key watch item for margins
- Cash and restricted cash of $689.5M at September 30, 2025; free cash flow burn guidance of $225–$235M maintained
03—Questions
Frequently Asked Questions
What drove the strong revenue growth in the third quarter?
Revenue grew 39% to $265.2M, led by Oncology test volume growth of 40% (Guardant360 Liquid, Tissue and Reveal), the early ramp of the Shield screening test, which contributed $24.1M, and a 18% increase in Biopharma & Data revenue, partly due to service-agreement milestones.
Why did management raise full-year revenue guidance?
The raised guidance of $965–$970M reflects stronger Oncology growth now expected at about 25% (up from about 20%), with volume growth above 30%, and a significant increase in Screening revenue expectations to $71–$73M based on higher projected Shield volume of 80,000–82,000 tests.
Is Guardant approaching profitability?
Not yet on a GAAP basis. The Q3 GAAP net loss was $92.7M and the non-GAAP net loss was $48.3M, though both improved year over year. Adjusted EBITDA loss narrowed to $45.5M, and free cash flow burn was $(45.8)M, an improvement from $(55.3)M in the prior-year quarter.
What are the main risks to watch from this report?
Operating expenses are rising to support the Shield launch, with non-GAAP opex guidance raised to $865–$875M. Investors should monitor whether Shield volume and screening revenue reach guidance, the sustainability of Biopharma & Data growth given its reliance on milestones, and the company's ongoing cash burn of $225–$235M for the year, against a cash balance of $689.5M.
What regulatory and commercial milestones were disclosed?
Guardant submitted its Guardant360 Liquid PMA application to the FDA, submitted Reveal immuno-oncology monitoring data to MolDx for Medicare reimbursement, received new Guardant360 companion diagnostic approvals for breast cancer and non-small cell lung cancer, expanded Shield to include multi-cancer detection, and formed collaborations with Quest Diagnostics and PathGroup to broaden Shield access.
04—Continue